Zimmer Biomet announced today that it named Embecta President and CEO Devdatt “Dev” Kurdikar to its board of directors.
Kurdikar has served as CEO of Embecta since the pure play diabetes business spun off from BD in 2022. He also serves on the board of directors at AdvaMed.
“We are pleased to welcome Dev to the ZB board,” said Chris Begley, chair of the Zimmer Biomet’s board of directors. “Dev brings a wealth of medtech, innovation and leadership experience that will be invaluable to ZB as we further advance our strategic priorities and mission to alleviate pain and improve people’s lives.”
Kurdikar previously served as worldwide president of Diabetes Care at BD, holding that post from 2021 until the spin. Before BD, he served as president and CEO of Cardiac Science Corporation from 2016 to 2019. Prior to that, he held the post of VP and GM for men’s health within Boston Scientific’s Urology and Pelvic Health unit.
Additionally, Kurdikar had the same position at American Medical Systems, leading the company’s men’s health business through its carve-out, sale and integration into Boston Scientific. He also spent 11 years in roles of increasing responsibility at Baxter.
Read also: Embecta CEO sees GLP-1 opportunities as company progresses on insulin patch pump.
